These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. [Testing of some N-lost-compounds by screening test for cytostatic activity (author's transl)]. Keitel R; Pöge AW Arch Geschwulstforsch; 1974; 43(2):168-71. PubMed ID: 4849880 [No Abstract] [Full Text] [Related]
64. From cells to QSAR: Alternative predictive models in toxicology. Sambuy Y; Bassi AM; Scanarotti C; Caloni F ALTEX; 2017; 34(1):168-171. PubMed ID: 28105479 [No Abstract] [Full Text] [Related]
65. [Planning of clinical studies based on results of animal experiments]. Radielović P Med Arh; 1972; 26(3):39-42. PubMed ID: 4562219 [No Abstract] [Full Text] [Related]
67. [Reliability of preclinical tests--predictability of results in man based on studies in laboratory animals]. Danysz A Pol Tyg Lek; 1992 Dec 21-28; 47(51-52):1126-30. PubMed ID: 1307101 [No Abstract] [Full Text] [Related]
68. JALA special issue: microengineered cell- and tissue-based assays for drug screening and toxicology applications. Huh DD; Kim DH J Lab Autom; 2015 Apr; 20(2):79-81. PubMed ID: 25795434 [No Abstract] [Full Text] [Related]
69. Principles for pre-clinical testing of drug safety. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser; 1966; 341():1-22. PubMed ID: 4959033 [No Abstract] [Full Text] [Related]
70. Carcinogenic potential of drugs. Adamson RH; Sieber SM J Environ Pathol Toxicol; 1980 Mar; 3(4 Spec No):377-85. PubMed ID: 6993614 [No Abstract] [Full Text] [Related]
71. The principles and practice of toxigenomics: applications and opportunities. Pennie WD; Tugwood JD; Oliver GJ; Kimber I Toxicol Sci; 2000 Apr; 54(2):277-83. PubMed ID: 10774809 [No Abstract] [Full Text] [Related]
73. A clinical scientist's view of preclinical drug testing requirements. Dayan AD Hum Exp Toxicol; 1991 Nov; 10(6):395-7. PubMed ID: 1687848 [No Abstract] [Full Text] [Related]
74. [Preliminary steps before the first use of a drug in man]. Duchêne-Marullaz P Rev Prat; 1983 Jan; 33(1-2):7-11. PubMed ID: 6823542 [No Abstract] [Full Text] [Related]
75. Impact of dosing schedule in animal experiments on compound progression decisions. Chen C Drug Discov Today; 2019 Feb; 24(2):371-376. PubMed ID: 30448352 [TBL] [Abstract][Full Text] [Related]
76. [The screening of the photosensitive and effective constituents of Hypocrella bambusae (author's transl)]. Wang XY Zhong Yao Tong Bao; 1981 Sep; 6(5):29-31. PubMed ID: 6210451 [No Abstract] [Full Text] [Related]
78. [Required knowledge of the action of new substances to be used for clinical treatment (author's transl)]. Trcka V Cesk Gynekol; 1973 Sep; 38(8):569-70. PubMed ID: 4587720 [No Abstract] [Full Text] [Related]
79. [Bayes' theorem in medical diagnosis (author's transl)]. Virnich H; Winkler C Methods Inf Med; 1976 Oct; 15(4):211-6. PubMed ID: 792629 [No Abstract] [Full Text] [Related]
80. Whole animal models in safety evaluation. Schach von Wittenau M Pharmacol Rev; 1984 Jun; 36(2 Suppl):177S-182S. PubMed ID: 6473502 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]